Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment.

导出 LinkOut

翻译打印收藏纠错

作者： Youlu,Chen ^[1] ; Yong,Zeng ^[2] ; Xiaowei,Zhu ^[1] ; Lifu,Miao ^[3] ; Xiaoyu,Liang ^[4] ; Jianwei,Duan ^[1] ; Huiyang,Li ^[1] ; Xinxin,Tian ^[1] ; Liyun,Pang ^[1] ; Yongxiang,Wei ^[1] ; Jing,Yang ^[2]

作者单位： Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, 300192, PR China. ^[1] Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, PR China. ^[2] Henan Center for Patent Examination and Cooperation of the Patent Office of the State Intellectual Property Office, Henan, 450002, PR China. ^[3] Heart Center, The First Hospital of Tsinghua University, Beijing, 100016, PR China. ^[4] Biomedical Barriers Research Center, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, PR China. ^[5]

关键词 Atherosclerosis Glycolysis HIF-1α Hypoxia Paclitaxel Sirolimus

DOI 10.1016/j.bioactmat.2020.09.005

PMID 33024904

发布时间 2023-11-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览22

Bioactive materials

2021年6卷3期

880-889页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment.

Bioactive materials

相似文献

Bioactive materials

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment.

Bioactive materials

相似文献

Bioactive materials

相关期刊

检索历史清除